Sold as Iplex. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Mecasermin Rinfabate Recombinant (sold as Iplex), first approved Dec 12, 2005, with 0 new uses approved and 0 published complete response letters.
| Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 LevelsGrowth Hormone Deficiency · Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Not applicable | Not yet recruiting | Sep 15, 2025 |
| Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)Gulf War Syndrome, Adult Growth Hormone Deficiency · Baylor College of Medicine | Phase 2 | Recruiting | May 2, 2022 |
| A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short StatureDwarfism · Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 2 | Active, not recruiting | Aug 21, 2017 |
| A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsBronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity · OHB Neonatology Ltd. | Phase 2 | Active, not recruiting | Aug 17, 2017 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
